AKTX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Akari Therapeutics PLC · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 7.86 USD
-9.7% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -16.3% below the Trend Line and sits at 10.4% of its 52-week range. The latest completed week returned -9.7%, after a -24.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 53/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 10d.

Setup score 21 out of 100
Latest Close 7.86 USD 31 Jul 2026
1W Return -9.7% latest completed week
4W Return -24.5% short-term follow-through
12W Return 25.8% quarterly tape
Trend Breadth 7.7% 4 of 52 weeks active
Volume Ratio 0.0x vs 13-week average
What is working
  • The trend backdrop is active with a 4-week active streak.
  • Activity pressure is positive on the latest completed week.
  • 4 accumulation markers appear in the recent smart-money tape.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 38.18% based on similar historical setup states.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -9.7% Latest completed week; four-week move -24.5%. Indicator stack 18/59 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 38.18% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 53/100 conviction; expected move 39.1%. News sentiment 53/100 54 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -16.3% below the Trend Line and sits at 10.4% of its 52-week range. The latest completed week returned -9.7%, after a -24.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.0x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3712-week average 0.23

12-week confirmation

Trend active4/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.37Current proprietary activity-pressure read.
Buy signals2Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

4 accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -24.5% over four weeks, 25.8% over 12 weeks, and -80.5% over one year. The current trend has remained active for 4 consecutive weeks.

Performance by holding period

1W-9.7%
4W-24.5%
12W25.8%
26W-16.2%
52W-80.5%
Active trend streak4 weeks
Active weeks in one year4
Trend breadth7.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.66Latest activity-pressure read.
Pressure change-35.9%Four-week change in activity pressure.
Leadership-58.35Latest relative-leadership reading.
RS change-6.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 61% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength74/100Blend of value, momentum, and quality. Underlying universe rank 27; rank 1 is best.
Value62/100Relative valuation strength. Underlying universe rank 39; rank 1 is best.
Quality60/100Profitability and accounting quality. Underlying universe rank 41; rank 1 is best.
Momentum62/100Medium-term price momentum. Underlying universe rank 39; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-82.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-179.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-61.4%
Net share repurchases relative to market value.
Shareholder yield
-61.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

AKTX shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.00, expected move of 39.1%, and Sharemaestro trend signal active.

Conviction53/100
Expected move39.1%
Put/call volume0.00
Pressure100
Speculation4
Volatility96
Trend agreement0
Open options detail
Insider activity15 / 0

15 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment53/100

Weighted news tone is neutral across 54 relevant articles.

13 positive · 35 neutral · 6 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move39.1%Nearest-chain priced movement where available.
52-week drawdown-84.2%Distance below the 52-week high.
13-week volatility116.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher7 of 2618 weeks finished lower.
Best week+423.5%Week of 22 May.
Worst week-44.2%Week of 15 May.
Latest week-9.7%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains2
Flat weeks1
Modest losses5
Sharp losses13
Recent vol116.4%13-week weekly-return volatility.
Base vol60.9%52-week weekly-return volatility.
Up/down split17/34Count of positive and negative weeks in the 52-week window.
Average skew35.3% / -12.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape23/100

Trend, activity pressure, participation, and risk combine to a 23/100 tape read.

 Indicator analysis50/100

Latest 12-week confirmation: trend 4/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.37; No reversal markers Next-Week ExpectancyNegative 38.18%

Next-week expectancy is negative with a 38.18% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors64/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 97 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options36/100

AKTX shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.00, expected move of 39.1%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 39.1% Sentiment53/100

Weighted news tone is neutral across 54 relevant articles.

Price to book forward of Akari Therapeutics Plc – NASDAQ:AKTX Insiders15 / 0

15 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20267.86 USD-9.7%9.39 USD65.81 USD0.66-58.35169.0KOn
24 Jul 20268.70 USD-21.0%9.52 USD67.12 USD0.86-55.57211.5KOn
17 Jul 202611.01 USD-20.7%9.58 USD68.18 USD1.01-47.05237.3KOn
10 Jul 202613.88 USD33.3%9.56 USD69.00 USD1.04-38.59451.7KOn
3 Jul 202610.41 USD-3.0%9.62 USD69.79 USD1.04-54.85588.7KOff
26 Jun 202610.73 USD-1.9%9.72 USD70.64 USD1.09-54.94524.2KOff
19 Jun 202610.94 USD-18.4%10.01 USD71.44 USD1.14-57.80285.4KOff
12 Jun 202613.40 USD-11.1%10.25 USD72.20 USD1.27-48.91272.0KOff
5 Jun 202615.07 USD-8.3%10.51 USD72.92 USD1.03-43.38650.7KOff
29 May 202616.43 USD-10.1%10.86 USD73.62 USD0.92-43.135.2MOff
22 May 202618.27 USD423.5%11.31 USD74.35 USD0.66-37.4639.4MOff
15 May 20263.49 USD-44.2%11.69 USD75.18 USD0.34-88.35252.0KOff
8 May 20266.25 USD14.3%12.64 USD76.22 USD0.30-80.0488.1KOff
1 May 20265.47 USD-5.7%13.67 USD77.13 USD-0.10-82.31135.3KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.